In:
Multiple Sclerosis Journal, SAGE Publications, Vol. 3, No. 6 ( 1997-12), p. 370-376
Abstract:
Due to the modest benefit, inconvenience and high cost of currently available therapies for MS, it is appropriate to seek alternative treatments. Based on anecdotal evidence suggestive of benefit for IVIG in MS, we conducted an open-label, unblinded protocol of IVIG in nine MS patients. The patients were given induction doses of IVIG followed by monthly boosters for I year and had clinical, MRI and CSF analyses performed. Patients included were both progressive and relapsing. There was no clinical benefit nor apparent MRI benefit utilizing this protocol. During treatment, the majority of patients continued to progress or have attacks and MRI demonstrated continued accumulation of T2-weighted lesions. CSF was unaffected by treatment
Type of Medium:
Online Resource
ISSN:
1352-4585
,
1477-0970
DOI:
10.1177/135245859700300602
Language:
English
Publisher:
SAGE Publications
Publication Date:
1997
detail.hit.zdb_id:
2008225-3